EGFR 受体酪氨酸激酶 (RTK) 家族包含四种不同的受体:EGFR(也称为 ErbB-1/HER1)、ErbB-2(neu、HER2)、ErbB-3(HER3)和 ErbB-4(HER4)。所有 EGFR 家族成员都具有模块化结构,由胞外配体结合结构域、单个疏水跨膜区和含有高度保守的酪氨酸激酶结构域的胞内部分组成。ErbB 受体酪氨酸激酶 (RTK) 家族将胞外生长因子配体的结合与胞内信号通路偶联,从而调节多种生物反应,包括增殖、分化、细胞运动和存活。十种生长因子及其 ErbB 特异性为:EGF、双调蛋白 (AR) 和 TGF 与 ErbB-1 结合; β细胞调节蛋白和表皮调节蛋白可结合 ErbB-1 和 ErbB-4;神经调节蛋白(也称为神经调节蛋白和 Neu 分化因子)NRG-1 和 NRG-2 可结合 ErbB-3 和 ErbB-4;NRG-3 和 NRG-4 可结合 ErbB-4。没有已知的配体可结合 ErbB-2。通过 ErbB 诱导的三种最典型的信号通路是 Ras-丝裂原活化蛋白激酶 (Ras-MAPK)、磷脂酰肌醇 3 激酶-蛋白激酶 B (PI3K-PKB/Akt) 和磷脂酶 C-蛋白激酶 C (PLC-PKC) 通路。
The EGFR family of receptor tyrosine kinases (RTK) comprises four distinct receptors: the EGFR (also known as ErbB-1/HER1), ErbB-2 (neu, HER2), ErbB-3 (HER3) and ErbB-4 (HER4). All EGFR family members are characterized by a modular structure consisting of an extracellular ligand-binding domain, a single hydrophobic transmembrane region, and the intracellular part harbouring the highly conserved tyrosine kinase domain. The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation, differentiation, cell motility, and survival. Ten growth factors and their ErbB specificities are: EGF, amphiregulin (AR), and TGF bind ErbB-1; betacellulin, and epiregulin bind both ErbB-1 and ErbB-4; the neuregulins (also called heregulins and Neu differentiation factors) NRG-1 and NRG-2 bind ErbB-3 and ErbB-4; and NRG-3 and NRG-4 bind ErbB-4. No known ligand binds ErbB-2. The three best characterized signaling pathways induced through ErbBs are Ras-mitogen-activated protein kinase (Ras-MAPK), phosphatidylinositol 3 kinase-protein kinase B (PI3K-PKB/Akt), and phospholipase C-protein kinase C (PLC-PKC) pathways.
Anti-HER3 Antibody (Ab562) 是一种抗 HER3 单克隆抗体,可用于合成抗体-药物偶联物 (ADC) AMT-562 (MS-U23687)。
HLX-22 是一种靶向 HER2 的人源化单克隆抗体,与 Trastuzumab (MS-U55108) 联用可诱导 HER2 过表达的乳腺癌和胃癌细胞发生凋亡 (apoptosis),并对晚期实体瘤具有强效抗肿瘤活性。
MM-151 是一种靶向 EGFR 的人源化 IgG1 单克隆抗体,可与 EGFR 胞外结构域 (ECD) 的多个区域结合,降低 EGFR 耐药的循环游离肿瘤 DNA 中的突变,显著抑制 EGFR 信号传导和细胞生长,并可用于耐药性癌症研究,例如结直肠癌、非小细胞肺癌和三阴性乳腺癌。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号